Taysha Gene Therapies (TSHA) Accounts Payables (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Accounts Payables data on file, last reported at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 5.5% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 5.5% YoY), and the FY2025 full-year result was $6.3 million, up 74.69% from the prior year.
• Accounts Payables declined to $4.6 million in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $24.0 million in Q2 2022 to a low of $3.6 million in Q4 2024.
• A 5-year average of $9.5 million and a median of $7.7 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 438.75% in 2022 and tumbled 59.08% in 2023, its largest moves.
• Tracing TSHA's Accounts Payables over 5 years: stood at $10.9 million in 2022, then sank by 41.84% to $6.4 million in 2023, then sank by 43.58% to $3.6 million in 2024, then surged by 74.69% to $6.3 million in 2025, then retreated by 27.27% to $4.6 million in 2026.
• Business Quant data shows TSHA's Accounts Payables at $4.6 million in Q1 2026, $6.3 million in Q4 2025, and $5.4 million in Q3 2025.